Keymed Biosciences (KYM Biosciences)
Chinese biotech whose joint venture KYM Biosciences created the Claudin 18.2 ADC CMG901, licensed to AstraZeneca in 2023.
KYM Biosciences (70% Keymed, 30% Lepu Biopharma) licensed CMG901 (now sonesitatug vedotin, AZD0901) to AstraZeneca for $63M upfront and up to $1.1B in milestones (February 2023). AstraZeneca runs the phase 3 CLARITY-Gastric01 programme.
Pages like this
not linked directly; found by shared links- TrialCLARITY-Gastric 01
Shares Sonesitatug vedotin, Claudin 18.2, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC).
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares Sonesitatug vedotin, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonChangsong Qi
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonJeeyun Lee
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- TargetClaudin 6
- InstitutionOlivia Newton-John Cancer Wellness and Research Centre
Shares Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC).
- PersonMin-Hee Ryu
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonLin Shen
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer.